Presurgical Trial of Metformin in Overweight and Obese Patients with Newly Diagnosed Breast Cancer

被引：64

作者：

Kalinsky, Kevin ^{[1
,2
]}

Crew, Katherine D. ^{[1
,2
,3
,4
]}

Refice, Susan ^{[1
]}

Xiao, Tong ^{[3
,4
]}

Wang, Antai ^{[2
,3
,4
]}

Feldman, Sheldon M. ^{[2
,5
]}

Taback, Bret ^{[2
,5
]}

Ahmad, Aqeel ^{[2
]}

Cremers, Serge ^{[6
]}

Hibshoosh, Hanina ^{[2
,7
]}

Maurer, Matthew ^{[1
,2
]}

Hershman, Dawn L. ^{[1
,2
,3
,4
]}

机构：

[1] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA

[2] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Coll Phys & Surg, New York, NY 10032 USA

[3] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, Coll Phys & Surg, New York, NY 10032 USA

[4] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, Coll Phys & Surg, New York, NY 10032 USA

[5] Columbia Univ, Coll Phys & Surg, Dept Surg, New York, NY 10032 USA

[6] Columbia Univ, Dept Med, Lab Irving Inst Clin & Translat Res, Coll Phys & Surg, New York, NY 10032 USA

[7] Columbia Univ, Dept Pathol & Cell Biol, Coll Phys & Surg, New York, NY 10032 USA

来源：

CANCER INVESTIGATION | 2014年 / 32卷 / 04期

基金：

美国国家卫生研究院;

关键词：

Presurgical; Metformin; Ki-67; Hispanic; Breast cancer; Insulin resistance; POSTMENOPAUSAL WOMEN; INSULIN-RESISTANCE; RESPONSES; GLUCOSE; LEPTIN; RECOMMENDATIONS; TAMOXIFEN; AMERICAN; KINASE; KI67;

D O I：

10.3109/07357907.2014.889706

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients. Methods: Metformin 1,500 mg daily was administered to 35 nondiabetics with stage 0-III BC, bodymass index (BMI) >= 25 kg/m(2). The primary endpoint was tumor proliferation change (i.e., ki-67). Tumor proliferation change was compared to untreated historical controls, matched by age, BMI, and stage. Results: There was no reduction in ln(ki- 67) after metformin (p = .98) or compared to controls (p = .47). There was a significant reduction in BMI, cholesterol, and leptin. Conclusion: Despite no proliferation changes, we observed reductions in other relevant biomarkers.

引用

页码：150 / 157

页数：8

共 38 条

[1] Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial [J].

Bonanni, Bernardo ;

Puntoni, Matteo ;

Cazzaniga, Massimiliano ;

Pruneri, Giancarlo ;

Serrano, Davide ;

Guerrieri-Gonzaga, Aliana ;

Gennari, Alessandra ;

Trabacca, Maria Stella ;

Galimberti, Viviana ;

Veronesi, Paolo ;

Johansson, Harriet ;

Aristarco, Valentina ;

Bassi, Fabio ;

Luini, Alberto ;

Lazzeroni, Matteo ;

Varricchio, Clara ;

Viale, Giuseppe ;

Bruzzi, Paolo ;

DeCensi, Andrea .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2593-2600

[2] Increased cancer-related mortality for patients with type 2 diabetes who use sulforrylureas or insulin [J].

Bowker, SL ;

Majumdar, SR ;

Veugelers, P ;

Johnson, JA .

DIABETES CARE, 2006, 29 (02) :254-258

[3] Prevalence of diabetes and impaired fasting glucose in adults in the US population - National Health and Nutrition Examination Survey 1999-2002 [J].

Cowie, Catherine C. ;

Engelgau, Michael M. ;

Rust, Keith F. ;

Saydah, Sharon H. ;

Byrd-Holt, Danita D. ;

Williams, Desmond E. ;

Eberhardt, Mark S. ;

Geiss, Linda S. ;

Flegal, Katherine M. ;

Gregg, Edward W. .

DIABETES CARE, 2006, 29 (06) :1263-1268

[4] Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer [J].

DeCensi, A. ;

Guerrieri-Gonzaga, A. ;

Gandini, S. ;

Serrano, D. ;

Cazzaniga, M. ;

Mora, S. ;

Johansson, H. ;

Lien, E. A. ;

Pruneri, G. ;

Viale, G. ;

Bonanni, B. .

ANNALS OF ONCOLOGY, 2011, 22 (03) :582-587

[5] Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome [J].

Diamanti-Kandarakis, E ;

Kouli, C ;

Tsianateli, T ;

Bergiele, A .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1998, 138 (03) :269-274

[6] Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer - A study from the IMPACT trialists [J].

Dowsett, M ;

Ebbs, SR ;

Dixon, JM ;

Skene, A ;

Griffith, C ;

Boeddinghaus, I ;

Salter, J ;

Detre, S ;

Hills, M ;

Ashley, S ;

Francis, S ;

Walsh, G ;

Smith, IE .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2477-2492

[7]

Dowsett M, 2005, CLIN CANCER RES, V11, p951S

[8] Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer [J].

Dowsett, Mitch ;

Smith, Ian E. ;

Ebbs, Stephen R. ;

Dixon, J. Michael ;

Skene, Anthony ;

A'Hern, Roger ;

Salter, Janine ;

Detre, Simone ;

Hills, Margaret ;

Walsh, Geraldine .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (02) :167-170

[9] Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group [J].

Dowsett, Mitch ;

Nielsen, Torsten O. ;

A'Hern, Roger ;

Bartlett, John ;

Coombes, R. Charles ;

Cuzick, Jack ;

Ellis, Matthew ;

Henry, N. Lynn ;

Hugh, Judith C. ;

Lively, Tracy ;

McShane, Lisa ;

Paik, Soon ;

Penault-Llorca, Frederique ;

Prudkin, Ljudmila ;

Regan, Meredith ;

Salter, Janine ;

Sotiriou, Christos ;

Smith, Ian E. ;

Viale, Giuseppe ;

Zujewski, Jo Anne ;

Hayes, Daniel F. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (22) :1656-1664

[10] Optimizing the implementation of future treatment using surrogate end-points [J].

Dowsett, Mitch .

BREAST CANCER RESEARCH, 2008, 10 (Suppl 4)

← 1 2 3 4 →